S&P 500   3,369.68 (-0.31%)
DOW   29,252.67 (-0.49%)
QQQ   234.34 (-0.13%)
AAPL   317.52 (-2.29%)
FB   216.94 (+1.29%)
MSFT   187.08 (+0.93%)
GOOGL   1,521.55 (+0.19%)
AMZN   2,143.69 (+0.41%)
CGC   22.14 (+0.05%)
NVDA   289.87 (+0.03%)
BABA   220.07 (+0.20%)
MU   57.38 (-1.91%)
GE   12.88 (+0.31%)
TSLA   853.59 (+6.69%)
AMD   56.02 (+1.28%)
T   38.28 (+0.08%)
F   8.12 (+0.25%)
PRI   135.66 (-0.87%)
BAC   34.44 (-1.18%)
DIS   138.97 (-0.41%)
GILD   67.16 (-0.59%)
S&P 500   3,369.68 (-0.31%)
DOW   29,252.67 (-0.49%)
QQQ   234.34 (-0.13%)
AAPL   317.52 (-2.29%)
FB   216.94 (+1.29%)
MSFT   187.08 (+0.93%)
GOOGL   1,521.55 (+0.19%)
AMZN   2,143.69 (+0.41%)
CGC   22.14 (+0.05%)
NVDA   289.87 (+0.03%)
BABA   220.07 (+0.20%)
MU   57.38 (-1.91%)
GE   12.88 (+0.31%)
TSLA   853.59 (+6.69%)
AMD   56.02 (+1.28%)
T   38.28 (+0.08%)
F   8.12 (+0.25%)
PRI   135.66 (-0.87%)
BAC   34.44 (-1.18%)
DIS   138.97 (-0.41%)
GILD   67.16 (-0.59%)
S&P 500   3,369.68 (-0.31%)
DOW   29,252.67 (-0.49%)
QQQ   234.34 (-0.13%)
AAPL   317.52 (-2.29%)
FB   216.94 (+1.29%)
MSFT   187.08 (+0.93%)
GOOGL   1,521.55 (+0.19%)
AMZN   2,143.69 (+0.41%)
CGC   22.14 (+0.05%)
NVDA   289.87 (+0.03%)
BABA   220.07 (+0.20%)
MU   57.38 (-1.91%)
GE   12.88 (+0.31%)
TSLA   853.59 (+6.69%)
AMD   56.02 (+1.28%)
T   38.28 (+0.08%)
F   8.12 (+0.25%)
PRI   135.66 (-0.87%)
BAC   34.44 (-1.18%)
DIS   138.97 (-0.41%)
GILD   67.16 (-0.59%)
S&P 500   3,369.68 (-0.31%)
DOW   29,252.67 (-0.49%)
QQQ   234.34 (-0.13%)
AAPL   317.52 (-2.29%)
FB   216.94 (+1.29%)
MSFT   187.08 (+0.93%)
GOOGL   1,521.55 (+0.19%)
AMZN   2,143.69 (+0.41%)
CGC   22.14 (+0.05%)
NVDA   289.87 (+0.03%)
BABA   220.07 (+0.20%)
MU   57.38 (-1.91%)
GE   12.88 (+0.31%)
TSLA   853.59 (+6.69%)
AMD   56.02 (+1.28%)
T   38.28 (+0.08%)
F   8.12 (+0.25%)
PRI   135.66 (-0.87%)
BAC   34.44 (-1.18%)
DIS   138.97 (-0.41%)
GILD   67.16 (-0.59%)
Log in

Exelixis News Headlines (NASDAQ:EXEL)

$20.54
-0.23 (-1.11 %)
(As of 02/18/2020 10:25 AM ET)
Today's Range
$20.38
Now: $20.54
$21.06
50-Day Range
$17.00
MA: $18.70
$20.77
52-Week Range
$15.02
Now: $20.54
$25.31
Volume27,184 shs
Average Volume3.19 million shs
Market Capitalization$6.24 billion
P/E Ratio10.53
Dividend YieldN/A
Beta1.93

Headlines

Exelixis (NASDAQ EXEL) News Headlines

Source:
DateHeadline
Exelixis (EXEL) Scheduled to Post Quarterly Earnings on TuesdayExelixis (EXEL) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 18 at 1:28 AM
Michael Morrissey Sells 25,000 Shares of Exelixis, Inc. (NASDAQ:EXEL) StockMichael Morrissey Sells 25,000 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock
www.americanbankingnews.com - February 17 at 4:16 AM
Exelixis, Inc. (NASDAQ:EXEL) Director Alan M. Garber Sells 12,500 SharesExelixis, Inc. (NASDAQ:EXEL) Director Alan M. Garber Sells 12,500 Shares
www.americanbankingnews.com - February 17 at 4:16 AM
Exelixis (NASDAQ:EXEL) Stock Rating Reaffirmed by William BlairExelixis (NASDAQ:EXEL) Stock Rating Reaffirmed by William Blair
www.americanbankingnews.com - February 14 at 4:34 PM
Exelixis, Inc. Expected to Earn FY2022 Earnings of $1.96 Per Share (NASDAQ:EXEL)Exelixis, Inc. Expected to Earn FY2022 Earnings of $1.96 Per Share (NASDAQ:EXEL)
www.americanbankingnews.com - February 14 at 12:43 PM
Exelixis to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 25, 2020 - Yahoo FinanceExelixis to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 25, 2020 - Yahoo Finance
finance.yahoo.com - February 13 at 2:45 PM
Exelixis, Inc. (NASDAQ:EXEL) Director Sells $80,560.00 in StockExelixis, Inc. (NASDAQ:EXEL) Director Sells $80,560.00 in Stock
www.americanbankingnews.com - February 13 at 4:26 AM
Exelixis to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 25, 2020Exelixis to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 25, 2020
finance.yahoo.com - February 12 at 5:39 PM
Exelixis (NASDAQ:EXEL) Earns "Buy" Rating from Piper SandlerExelixis (NASDAQ:EXEL) Earns "Buy" Rating from Piper Sandler
www.americanbankingnews.com - February 12 at 6:59 AM
Exelixis, Inc. (NASDAQ:EXEL) Receives Consensus Rating of "Buy" from BrokeragesExelixis, Inc. (NASDAQ:EXEL) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 12 at 6:59 AM
Exelixis (EXEL) Outpaces Stock Market Gains: What You Should Know - Yahoo FinanceExelixis (EXEL) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
finance.yahoo.com - February 12 at 12:48 AM
Exelixis Reports Positive Results in Metastatic Castration-Resistant Prostate Cancer Study - Motley FoolExelixis Reports Positive Results in Metastatic Castration-Resistant Prostate Cancer Study - Motley Fool
www.fool.com - February 12 at 12:48 AM
Exelixis (EXEL) Outpaces Stock Market Gains: What You Should Know - NasdaqExelixis (EXEL) Outpaces Stock Market Gains: What You Should Know - Nasdaq
www.nasdaq.com - February 11 at 7:47 PM
Exelixis (EXEL) Outpaces Stock Market Gains: What You Should KnowExelixis (EXEL) Outpaces Stock Market Gains: What You Should Know
finance.yahoo.com - February 11 at 7:47 PM
Exelixis (EXEL) PT Raised to $35 at SunTrust Following Strong KOL Feedback - StreetInsider.comExelixis (EXEL) PT Raised to $35 at SunTrust Following Strong KOL Feedback - StreetInsider.com
www.streetinsider.com - February 11 at 2:46 PM
Exelixis cabozantinib combo shows encouraging action in prostate cancer - Seeking AlphaExelixis' cabozantinib combo shows encouraging action in prostate cancer - Seeking Alpha
seekingalpha.com - February 11 at 9:29 AM
Exelixis (EXEL) Announces Encouraging Results for Cabozantinib in Combination With Atezolizumab in Metastatic CRPC - StreetInsider.comExelixis (EXEL) Announces Encouraging Results for Cabozantinib in Combination With Atezolizumab in Metastatic CRPC - StreetInsider.com
www.streetinsider.com - February 10 at 5:57 PM
Exelixis Announces Encouraging Results for Cabozantinib in Combination With Atezolizumab in Metastatic Castration-Resistant Prostate CancerExelixis Announces Encouraging Results for Cabozantinib in Combination With Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
finance.yahoo.com - February 10 at 5:57 PM
Exelixis, Inc. (NASDAQ:EXEL) CMO Gisela Schwab Sells 50,000 SharesExelixis, Inc. (NASDAQ:EXEL) CMO Gisela Schwab Sells 50,000 Shares
www.americanbankingnews.com - February 10 at 4:23 AM
$240.92 Million in Sales Expected for Exelixis, Inc. (NASDAQ:EXEL) This Quarter$240.92 Million in Sales Expected for Exelixis, Inc. (NASDAQ:EXEL) This Quarter
www.americanbankingnews.com - February 9 at 3:50 AM
 Analysts Anticipate Exelixis, Inc. (NASDAQ:EXEL) to Post $0.15 EPS Analysts Anticipate Exelixis, Inc. (NASDAQ:EXEL) to Post $0.15 EPS
www.americanbankingnews.com - February 7 at 10:57 AM
Exelixis Announces Webcasts of Investor Conference Presentations in February - Business WireExelixis Announces Webcasts of Investor Conference Presentations in February - Business Wire
www.businesswire.com - February 6 at 10:21 PM
Exelixis (EXEL) Gains But Lags Market: What You Should Know - Yahoo FinanceExelixis (EXEL) Gains But Lags Market: What You Should Know - Yahoo Finance
finance.yahoo.com - February 4 at 11:07 PM
Exelixis (EXEL) Gains But Lags Market: What You Should KnowExelixis (EXEL) Gains But Lags Market: What You Should Know
finance.yahoo.com - February 4 at 11:06 PM
Exelixis, Inc. (NASDAQ:EXEL) CEO Michael Morrissey Sells 25,000 SharesExelixis, Inc. (NASDAQ:EXEL) CEO Michael Morrissey Sells 25,000 Shares
www.americanbankingnews.com - January 31 at 10:30 PM
Exelixis Announces Partner Takeda Files New Drug Application in Japan for CABOMETYX® (cabozantinib) for Advanced Hepatocellular Carcinoma - Yahoo FinanceExelixis Announces Partner Takeda Files New Drug Application in Japan for CABOMETYX® (cabozantinib) for Advanced Hepatocellular Carcinoma - Yahoo Finance
finance.yahoo.com - January 29 at 8:43 AM
Exelixis Announces Partner Takeda Files New Drug Application in Japan for CABOMETYX® (cabozantinib) for Advanced Hepatocellular CarcinomaExelixis Announces Partner Takeda Files New Drug Application in Japan for CABOMETYX® (cabozantinib) for Advanced Hepatocellular Carcinoma
www.businesswire.com - January 29 at 4:31 AM
Exelixis, Inc. (NASDAQ:EXEL) Short Interest UpdateExelixis, Inc. (NASDAQ:EXEL) Short Interest Update
www.americanbankingnews.com - January 28 at 5:20 PM
With Abbott, Exelixis and Penumbra expanding, Alameda (again) is a biotech hotspot - San Francisco Business Times - San Francisco Business TimesWith Abbott, Exelixis and Penumbra expanding, Alameda (again) is a biotech hotspot - San Francisco Business Times - San Francisco Business Times
www.bizjournals.com - January 28 at 2:15 PM
Needham & Company LLC Reiterates Buy Rating for Exelixis (NASDAQ:EXEL)Needham & Company LLC Reiterates Buy Rating for Exelixis (NASDAQ:EXEL)
www.americanbankingnews.com - January 27 at 2:16 PM
Roche Submits Application for Tecentriq-Avastin Combo in HCCRoche Submits Application for Tecentriq-Avastin Combo in HCC
finance.yahoo.com - January 27 at 1:03 PM
Exelixis up 1% premarket on Cabometyx data in liver cancer - Seeking AlphaExelixis up 1% premarket on Cabometyx data in liver cancer - Seeking Alpha
seekingalpha.com - January 24 at 8:13 AM
Exelixis Announces Results for Combination of Cabozantinib and Nivolumab With or Without Ipilimumab in Advanced Hepatocellular CarcinomaExelixis Announces Results for Combination of Cabozantinib and Nivolumab With or Without Ipilimumab in Advanced Hepatocellular Carcinoma
finance.yahoo.com - January 24 at 8:13 AM
Exelixis: Looking Good, Despite Stagnant Product Sales Guidance - Seeking AlphaExelixis: Looking Good, Despite Stagnant Product Sales Guidance - Seeking Alpha
seekingalpha.com - January 23 at 1:22 AM
Can Investors Excel in 2020 With Exelixis? - Motley FoolCan Investors Excel in 2020 With Exelixis? - Motley Fool
www.fool.com - January 22 at 3:22 PM
Can Investors Excel in 2020 With Exelixis?Can Investors Excel in 2020 With Exelixis?
www.fool.com - January 22 at 2:42 PM
How this East Bay biotech went from debt to expansionHow this East Bay biotech went from debt to expansion
finance.yahoo.com - January 21 at 11:26 PM
How Exelixis went from debt to expansion - San Francisco Business Times - San Francisco Business TimesHow Exelixis went from debt to expansion - San Francisco Business Times - San Francisco Business Times
www.bizjournals.com - January 21 at 6:25 PM
Exelixis: Whats Ahead For 2020 - Seeking AlphaExelixis: What's Ahead For 2020 - Seeking Alpha
seekingalpha.com - January 19 at 8:50 AM
Exelixis: Whats Ahead For 2020Exelixis: What's Ahead For 2020
seekingalpha.com - January 19 at 5:15 AM
GILD or EXEL: Which Is the Better Value Stock Right Now? - Yahoo FinanceGILD or EXEL: Which Is the Better Value Stock Right Now? - Yahoo Finance
finance.yahoo.com - January 18 at 1:42 AM
GILD or EXEL: Which Is the Better Value Stock Right Now?GILD or EXEL: Which Is the Better Value Stock Right Now?
finance.yahoo.com - January 17 at 3:41 PM
Exelixis, Inc. (EXEL) CEO Michael Morrissey on 38th Annual JPMorgan Healthcare Conference (Transcript) - Seeking AlphaExelixis, Inc. (EXEL) CEO Michael Morrissey on 38th Annual JPMorgan Healthcare Conference (Transcript) - Seeking Alpha
seekingalpha.com - January 15 at 2:26 AM
Does Exelixis, Inc. (NASDAQ:EXEL) Have A Good P/E Ratio? - Yahoo FinanceDoes Exelixis, Inc. (NASDAQ:EXEL) Have A Good P/E Ratio? - Yahoo Finance
finance.yahoo.com - January 14 at 4:25 PM
Does Exelixis, Inc. (NASDAQ:EXEL) Have A Good P/E Ratio?Does Exelixis, Inc. (NASDAQ:EXEL) Have A Good P/E Ratio?
finance.yahoo.com - January 14 at 4:25 PM
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo FinanceWill Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
finance.yahoo.com - January 13 at 4:35 PM
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
finance.yahoo.com - January 13 at 4:35 PM
UPDATE: SunTrust Starts Exelixis (EXEL) at Buy - StreetInsider.comUPDATE: SunTrust Starts Exelixis (EXEL) at Buy - StreetInsider.com
www.streetinsider.com - January 13 at 6:54 AM
Exelixis sees $245M in Q4 revenues - Seeking AlphaExelixis sees $245M in Q4 revenues - Seeking Alpha
seekingalpha.com - January 12 at 8:53 PM
Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial GuidanceExelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance
finance.yahoo.com - January 12 at 8:53 PM
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Featured Article: What does RSI mean?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel